timothy sykes logo
LLY Stock Extends Run As Obesity Franchise Dominates Thumbnail
G Google News

LLY Stock Extends Run As Obesity Franchise Dominates

ELLIS HOBBS•UPDATED OCT. 7, 2026, 12:32 PM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Eli Lilly and Company stocks have been trading up by 4.14 percent after bullish coverage spotlighted its obesity drug pipeline.

Key Takeaways

  • Wall Street is leaning bullish as JPMorgan lifts its LLY price target to $1,500, citing powerful incretin drug momentum and strong Zepbound Medicare demand into Q3 earnings.
  • Triple-agonist retatrutide delivered robust Phase 3 TRIUMPH‑2 results, supporting a planned 2027 BLA filing and adding more long‑run fuel to Eli Lilly’s obesity and diabetes engine.
  • Oral GLP‑1 Foundayo matched insulin glargine on cardiovascular safety while driving superior weight loss, A1C control, kidney protection, and sizable drops in cardiovascular and all‑cause mortality.
  • EloraTZP combo data showed up to 23.3% weight loss and sharp A1C cuts, though with more gastrointestinal‑driven discontinuations that traders should track as the program advances.
  • Once‑weekly insulin Onswik now has U.S. FDA approval, giving LLY another diabetes revenue pillar with convenience that can support broad adoption.

Candlestick Chart

Live Update At 12:32:09 EDT: On Wednesday, October 07, 2026 Eli Lilly and Company stock [NYSE: LLY] is trending up by 4.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

LLY is trading like a true market leader, and the tape backs it up. Over the past several weeks, Eli Lilly shares have held a tight range mostly between $1,140 and $1,190, now pushing to around $1,205. That steady grind higher, with only shallow pullbacks, tells traders big money is buying dips rather than bailing on strength.

Daily candles show repeated rebounds near the mid‑$1,130s–$1,150s, creating a clear support zone. The latest session opened near $1,173 and climbed to close just above $1,205, a strong intraday trend with higher lows all day on the 5‑minute chart. For short‑term traders, that intraday staircase pattern often signals aggressive institutional accumulation.

More Breaking News

Under the hood, Eli Lilly is printing the kind of fundamentals that usually support extended uptrends. Q2 2026 revenue hit $23.0B, up 48% year over year, powered by GLP‑1 heavyweights Mounjaro at $9.9B and Zepbound at $4.9B. Full‑year guidance now stands at $85–$87B. Margins are elite: gross margin at 83.4% and EBIT margin over 50%. Yes, LLY trades at a rich P/E near 38, but with revenue growing more than 39% over three years and massive free cash flow, the market is clearly paying for dominance.

Why Traders Are Watching LLY Right Now

This is what a full‑blown sector takeover looks like. LLY is not just riding one hit drug; Eli Lilly is building a layered obesity and diabetes fortress that traders have to respect.

Start with Zepbound. Fresh indirect comparisons show Eli Lilly’s drug delivering greater average weight loss and more patients hitting at least 20% body‑weight reduction versus Novo Nordisk’s high‑dose Wegovy, with similar dropout rates from side effects. Another analysis pegs Zepbound’s edge at roughly 4.5% more weight loss at the highest dose. For traders, that kind of efficacy lead supports premium pricing, sticky demand, and share gains in a market that is already huge and still expanding.

Then comes Foundayo, LLY’s oral GLP‑1. A large Phase 3 trial showed Foundayo is non‑inferior to insulin glargine on major cardiovascular events while actually beating insulin on weight loss, A1C, and multiple cardio‑metabolic outcomes, with notable cuts in cardiovascular and all‑cause mortality. Eli Lilly also reports Foundayo outperformed oral semaglutide in an indirect 52‑week comparison for weight and A1C, plus post‑hoc data showing up to a 57% modeled reduction in 10‑year diabetes risk and 18% less heart disease risk in high‑risk patients.

Add in retatrutide, LLY’s triple hormone agonist, posting Phase 3 TRIUMPH‑2 data with roughly 21% average weight loss and strong A1C and cardiovascular risk factor improvements, and the story gets longer‑dated. UBS and BMO are already flagging these second‑ and third‑generation assets—retatrutide, eloralintide combos like EloraTZP—as potential successors that can even outperform tirzepatide. On top of that, Eli Lilly has new FDA approvals in Onswik and a label expansion path for Jaypirca and EBGLYSS, showing this is a diversified pharma powerhouse, not a one‑trick GLP‑1 pony.

Conclusion

For active traders, LLY now trades at the intersection of big‑cap stability and high‑growth biotech momentum. Eli Lilly just delivered Q2 numbers that support its premium multiple, then layered on a wave of positive clinical and regulatory news: a cleaner insulin option with once‑weekly Onswik, outcomes‑heavy oral GLP‑1 data from Foundayo, a potential next‑gen winner in retatrutide, and mid‑stage EloraTZP results with weight loss north of 20%. Wall Street is reacting. JPMorgan has hiked its LLY price target to $1,500 and reaffirmed an Overweight view, while BMO and others keep pushing the obesity‑portfolio narrative.

The chart backs that optimism, with LLY grinding higher on strong volume, respecting support, and closing near highs. But traders still need to stay disciplined. Gastrointestinal‑driven discontinuations in EloraTZP, high expectations priced into Eli Lilly, and any setback in the obesity race could spark sharp swings.

This content is for educational and research purposes only, but the trading lesson is clear. As Tim Sykes likes to say, “Patterns repeat because human nature doesn’t change—your edge comes from recognizing them early and managing risk ruthlessly.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. LLY is a live case study in that idea: a leading name, a powerful trend, and a chart that rewards prepared traders who respect both the upside and the risk.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”